Alnylam下调2026年产品收入指引，股价盘中大跌

Microsoft surges on strong revenue outlook, maintained capex guidance
Introduction & Market Context
Alnylam Pharmaceuticals (NASDAQ:ALNY) presented its second quarter 2026 financial results on July 30, 2026, revealing robust revenue growth and a historic milestone for its flagship AMVUTTRA franchise, even as the company’s decision to lower full-year guidance triggered a sharp selloff that sent shares tumbling more than 25% to near 52-week lows.
The biotechnology company reported total net product revenues of $1.17 billion for the quarter, representing 74% year-over-year growth, with its TTR franchise generating $1.03 billion in net revenues, up 89% from the prior year period. AMVUTTRA became the company’s first product to surpass $1 billion in quarterly revenue, a milestone achieved just 15 months after its ATTR cardiomyopathy launch.
However, the company revised its 2026 total net product revenue guidance downward to $4.7-5.1 billion from a prior range of $4.9-5.3 billion, citing normalization in second-line patient demand that had been unusually elevated during the early launch period. The stock fell 25.19% to $214.41 in trading following the announcement, approaching its 52-week low of $206.89.
Quarterly Performance Highlights
The company’s Q2 2026 results demonstrated continued commercial momentum across multiple dimensions, as illustrated in the following summary of key achievements:
Total global net product revenues reached $1.172 billion in the second quarter, marking 74% year-over-year growth and 13% sequential growth from Q1 2026. The TTR franchise, comprising AMVUTTRA and ONPATTRO, drove the majority of this performance with $1.03 billion in combined revenues.
U.S. TTR revenues increased 15% quarter-over-quarter and 114% year-over-year, supported by strong demand growth, though partially offset by a $21 million inventory reduction and modest pricing pressure. International TTR revenues grew 7% sequentially and 31% year-over-year, driven by uptake in ATTR-CM sales in Japan, the United Kingdom, and Germany.
The company’s Rare disease franchise, consisting of GIVLAARI and OXLUMO, contributed $142 million in net product revenues, representing 11% year-over-year growth. Collaboration revenues totaled $47 million, down 23% from the prior year, while royalty revenues climbed 79% to $72 million.
Financial Performance and Margin Analysis
As shown in the following detailed financial summary, Alnylam’s profitability metrics improved substantially year-over-year despite some margin compression:
Non-GAAP operating income reached $318 million in Q2 2026, more than tripling from $95 million in the prior year period. The non-GAAP operating margin expanded to 25% from 12% a year earlier, reflecting improved operating leverage as revenue growth outpaced expense increases.
However, gross margin on product revenues declined to 75% from 79% in Q2 2025, primarily due to higher royalty payments associated with AMVUTTRA’s rapid sales growth. Total cost of goods sold, collaborations, and royalties increased to $298 million from $143 million in the prior year quarter.
Operating expenses continued to rise as the company invests in research and commercial expansion. Non-GAAP R&D expenses increased 38% year-over-year to $377 million, while non-GAAP SG&A expenses grew 14% to $297 million. Combined non-GAAP R&D and SG&A expenses totaled $674 million, up 26% from the prior year.
The company’s cash position strengthened to $3.31 billion in cash, cash equivalents, and marketable securities at quarter end, up from $2.91 billion at the end of 2025, providing substantial resources for continued pipeline investment and commercial expansion.
Revised Guidance and Market Reaction
The company’s updated 2026 guidance reflects a recalibration of growth expectations, as detailed in the following comparison:
Alnylam reduced its total net product revenue guidance to $4.7-5.1 billion from $4.9-5.3 billion, with the midpoint representing 64% year-over-year growth compared to 70% in the prior guidance. The TTR franchise outlook was lowered to $4.2-4.5 billion from $4.4-4.7 billion, a $200 million reduction at the midpoint.
Management attributed the revision to better understanding of demand patterns following the AMVUTTRA ATTR-CM launch. CEO Yvonne Greenstreet explained that second-line patient flow, which was elevated early in the launch due to pent-up demand, has normalized to more sustainable levels. The company now expects first-line patient starts to drive the majority of future growth.
Offsetting the product revenue reduction, Alnylam raised its net revenues from collaborations and royalties guidance to $575-625 million from $400-500 million, benefiting from stronger LEQVIO sales and higher Roche reimbursement tied to the ZENITH hypertension study. The company maintained its non-GAAP combined R&D and SG&A expense guidance at $2.7-2.8 billion.
TTR Franchise Leadership and Competitive Positioning
Despite the guidance adjustment, Alnylam’s presentation emphasized its strengthening position in the TTR market and pathway to market leadership by 2030, as illustrated in the following strategic framework:
The company’s AMVUTTRA launch trajectory has significantly outpaced comparable product launches, with quarterly revenue growth exceeding analogs such as OCREVUS, WINREVAIR, and VYVGART in the first five quarters post-launch. Management projects achieving its 2030 revenue goal of $5.5 billion with a 25% compound annual growth rate from 2025 to 2030.
The following breakdown shows the sustained growth in TTR franchise revenues across both U.S. and international markets:
Global TTR net product revenues increased $120 million sequentially in Q2 2026, with the U.S. contributing $106 million of the increase and rest-of-world markets adding $14 million. The U.S. TTR business grew 114% year-over-year, while international markets expanded 31%, demonstrating broad-based geographic momentum.
Alnylam highlighted AMVUTTRA’s differentiated clinical profile as a key competitive advantage:
The therapy is approved for both ATTR-CM and hATTR-PN in adults in the U.S., providing broader utility than competing stabilizers. Its quarterly dosing via healthcare provider-administered prefilled syringe offers a convenience advantage over daily oral therapies and monthly self-injections. Clinical data demonstrated consistency in treatment effect with or without background stabilizer use, supporting both first-line and second-line positioning.
Management identified several factors reinforcing their long-term TTR strategy, including normalization of second-line inflow volume after early concentration, establishment of AMVUTTRA as a first-line option, favorable competitive developments including delayed stabilizer genericization, and accelerating category growth driven by earlier diagnosis and treatment.
Clinical Evidence and Pipeline Development
The presentation emphasized robust clinical data supporting AMVUTTRA’s efficacy profile, particularly for early-stage patients:
Data from the HELIOS-B trial demonstrated powerful efficacy in the monotherapy population, with a hazard ratio of 0.577 for time-to-first cardiovascular event or all-cause mortality and 0.607 for all-cause mortality alone. Forest plot analyses showed that early patients with lower baseline NT-proBNP levels and younger age realized the greatest benefit, supporting first-line use strategies.
Looking ahead, Alnylam is advancing nucresiran, its next-generation RNAi therapeutic targeting TTR, through two pivotal Phase 3 trials:
The TRITON-CM study in ATTR-CM has been expanded from approximately 1,250 to 1,750 participants and targets a 2030 launch, while the TRITON-PN study in hATTR-PN with approximately 125 participants targets a 2028 launch. Nucresiran is designed to deliver greater than 95% TTR knockdown with potential for biannual dosing, representing a meaningful advancement over current therapies.
The company presented comparative data demonstrating RNAi’s superior knockdown efficacy:
Nucresiran achieved 95% median TTR knockdown with an estimated 99% of patients reaching the 80% knockdown threshold, compared to 91% median knockdown and 82% above threshold for vutrisiran, and 84% median knockdown and 67% above threshold for eplontersen. This deeper, more consistent knockdown could translate to improved clinical outcomes.
Management expressed high confidence in the TRITON-CM program based on three factors: the molecule’s RNAi mechanism with greater than 95% TTR knockdown, the event-driven study design enriched for patients most likely to benefit, and the company’s 15-year track record in TTR drug development with meticulous study execution.
Broader Pipeline and Strategic Innovation
Beyond TTR, Alnylam showcased an extensive pipeline spanning multiple therapeutic areas, as detailed in the following comprehensive overview:
The company’s pipeline includes programs in cardiovascular disease (zilebesiran for hypertension, rapirosiran for MASH), metabolic disorders (ALN-2232 and ALN-6222 for obesity, ALN-ANG3 for diabetic kidney disease), neuroscience (cemdisiran for myasthenia gravis, mivelsiran for Alzheimer’s disease, ALN-HTT02 for Huntington’s disease), and hematology (ALN-6400 for bleeding disorders).
In Q2 2026, the company announced a new artificial intelligence partnership with Inceptive to accelerate discovery timelines and unlock innovative oligonucleotide designs. Two Phase 2 trials were initiated for ALN-6400 in Von Willebrand Disease and mivelsiran in Down Syndrome-Associated Alzheimer’s Disease.
The following roadmap outlines near-term pipeline milestones and achievements:
For 2026, the company completed enrollment of the cAPPricorn-1 Phase 2 trial for mivelsiran in cerebral amyloid angiopathy, initiated Phase 2 trials in Alzheimer’s disease and a second bleeding disorder, and initiated a Phase 2 trial for ALN-4324 in type 2 diabetes. Expected second-half data readouts include ALN-HTT02 Phase 1 results, ALN-6400 Phase 1 and Phase 2 data, and ALN-2232 Phase 1 obesity data.
Strategic Vision: Alnylam 2030
The company outlined its long-term strategic framework targeting sustained growth and market leadership through 2030:
Alnylam’s "Alnylam 2030" strategy rests on three pillars: achieving global TTR leadership by leading the TTR market in revenue by 2030 and launching nucresiran in PN by 2028 and CM by 2030; growing through sustainable innovation by delivering two or more new transformative medicines beyond TTR with blockbuster potential and expanding to 10 tissue types and more than 40 clinical programs; and scaling with discipline by achieving 25%+ total revenue CAGR through 2030 and delivering approximately 30% non-GAAP operating margin.
To support these goals, the company plans to invest approximately 30% of revenues in non-GAAP R&D, including select external innovation, and maintain a pipeline filing rate of 3-4 new INDs per year.
Rare Disease Franchise Performance
While TTR products drove the majority of growth, Alnylam’s established rare disease franchise continued to deliver steady performance:
Total rare franchise net product revenues reached $142 million in Q2 2026, up 11% year-over-year and 13% quarter-over-quarter. GIVLAARI revenues grew 11% year-over-year, driven by an approximately 8% increase in global patients on therapy and timing of orders in partner markets. OXLUMO revenues also increased 11% year-over-year, supported by an approximately 8% increase in U.S. patients on therapy and 30% growth in partner markets.
Forward-Looking Challenges and Opportunities
Despite the strong quarter and long-term strategic vision, several near-term challenges emerged from the presentation and subsequent market reaction. The normalization of second-line demand, while anticipated, occurred faster than originally modeled, requiring a recalibration of 2026 expectations. Gross margin compression from higher royalty payments on AMVUTTRA sales may continue as the product scales.
The company also faces increasing R&D investment requirements to support its expanding pipeline, with non-GAAP R&D expenses up 38% year-over-year. Competitive dynamics in the ATTR market remain fluid, with management noting they have time to review recent competitive trial data and potentially adjust the TRITON-CM study design if warranted.
However, management emphasized several growth drivers that support confidence in the long-term trajectory. First-line patient starts now represent approximately 80% of category growth in the accelerating ATTR-CM market. The company is capturing more than 50% of new patient starts from AMVUTTRA-experienced prescribers and has added over 1,700 new prescribers since the ATTR-CM launch. Approximately one-third of all active TTR treaters have prescribed AMVUTTRA, leaving substantial room for prescriber base expansion.
Chief Commercial Officer Tolga Tanguler emphasized that "driving breadth of prescribers is key to unlocking our next wave of growth," with the company investing to capitalize on the expansion opportunity. CEO Greenstreet noted that unmet medical need is driving earlier diagnosis and treatment of patients, leading to growth in the number of physicians and healthcare systems treating ATTR-CM.
The guidance revision and subsequent stock decline underscore the high expectations embedded in growth-stage biotechnology valuations and the market’s sensitivity to changes in growth trajectory, even when absolute performance remains strong. With AMVUTTRA achieving blockbuster status in record time, a robust pipeline advancing through clinical development, and a clear strategic vision for 2030, Alnylam’s long-term fundamentals appear intact despite near-term growth rate moderation.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.